

Reach for the Stars Wednesday, March 8

- 7:30am- 5:00pm Grant Review Committee Meeting (by invitation)
- 12:00-5:30pm **Melanoma Patients, Advocates & Foundations Forum**
Chair: Cody Barnett, MPH; MRA Director of Communications and Patient Engagement
- 4:00-8:00pm Retreat Registration open
- 5:30-6:00pm Sponsor Toast/Reception
- 6:00-7:30pm Opening Reception
- 7:00-9:30pm Friends of MRA Dinner [GRC and invited guests only]

Thursday, March 9

- 6:30am-6:00pm Registration
- 7:30-8:45am General Breakfast
- 7:30-8:45 am Young Investigators Breakfast (by invitation)
- 9:00-9:15am **Opening Remarks Day 1**
Marc Hurlbert, PhD; MRA CEO
TBD, Patient Advocate
TBD, Patient Advocate
Stephanie Kauffman, MRA President and COO
- 9:15-9:45am **Keynote Lecture 1: TBD**
- 9:45-11:55am **Scientific Session 1: Artificial Intelligence and Imaging in Melanoma Detection and Prognosis**
Chair: Maria Wei, MD, PhD; Professor of Dermatology; University of California, San Francisco
- 9:45-10:10 am **Albert Chiou, MD, MBA;** Clinical Associate Professor of Dermatology; Stanford University
AI-Augmented Melanoma Triage and Diagnosis: A Prospective Multi-Site Study

- 10:10-10:30 am **Jesse Wilson, PhD**; Assistant Professor of Electrical and Computer Engineering; Colorado State University
Developing Advanced Non-invasive Histology Techniques
- 10:30-11:00 am Break
- 11:00- 11:25 am **Michael Postow, MD**; Assistant Attending Physician; Chief, Melanoma Service; Memorial Sloan-Kettering Cancer Center
CD8+ Cell Imaging During Neoadjuvant ImmunoTherapy (T-IT Neo Trial)
- 11:25-11:50 am **Pratip Bhattacharya, PhD**; Associate Professor, Department of Cancer Systems Imaging; University of Texas M.D. Anderson Cancer Center
Imaging Biomarkers for Immunotherapy Resistance in Melanoma in Vivo
- 11:50am-12:00pm Transition to lunch
- 12:00pm-1:20pm Networking Lunch and General Roundtables
- | | |
|--|--|
| <i>Acral + Mucosal Melanoma Patient Registry</i> | <i>Metastasis and tumor dormancy</i> |
| <i>Biomarkers – ‘liquid biopsy’, ctDNA, tumor biomarkers</i> | <i>Microbiome</i> |
| <i>Brain metastasis and leptomeningeal disease</i> | <i>Neoadjuvant and adjuvant therapy</i> |
| <i>Clinical trials – patient recruitment and engagement, trial design</i> | <i>Prevention (primary prevention)</i> |
| <i>Dermatology fellows</i> | <i>Starting a company/venture philanthropy</i> |
| <i>Diversity – Women & Underrepresented groups in melanoma research and care</i> | <i>Targets & drug discovery for new treatments</i> |
| <i>Early Detection & Diagnosis (AI, imaging, machine learning)</i> | <i>Tumor microenvironment</i> |
| <i>Genomics – Role of genetics, genomics & epigenetics</i> | <i>Uveal melanoma</i> |
| <i>irAE – understanding immune-related adverse events</i> | <i>Vaccines and cell-based therapies</i> |
| <i>Mentoring / mentorship</i> | |
- 1:30-3:00pm **Scientific Session 2: Novel Treatment Strategies for Melanoma**
Chair: Tanisha Jackson, PhD; MRA Scientific Program Director
- 1:30-1:55pm **Iman Osman, MD**; Baer Professor of Dermatology, New York University Grossman School of Medicine
Developing a Predictive Tool Using Machine Learning Algorithm in Melanoma

- 1:55-2:15pm **Lixin Wan, PhD**; Assistant Professor, Moffitt Cancer Center and Research Institute
Targeting the JNK-ITCH Signaling Pathway in Melanoma
- 2:15-2:35pm **Gatien Moriceau, PhD**; Assistant Adjunct Professor, University of California, Los Angeles
Uncoupling MEK and ERK to Treat Melanoma
- 2:35-2:55pm **Matthew Vesely, MD, PhD**; Assistant Professor, Yale University School of Medicine
Determining the Immune Inhibitory Landscape in Melanoma
- 2:55-3:25 Break
- 3:25-4:25pm Scientific Session 3: Rare Melanomas**
Chair: Joan Levy, PhD; MRA Senior Director of Special Projects
- 3:25-3:45pm **Carla Daniela Robles-Espinosa, PhD**; Assistant Professor, National Autonomous University of Mexico
Defining Mediators of Metastatic Spread in Acral Melanoma
- 3:45-4:05pm **J. Silvio Gutkind, PhD**; Distinguished Professor and Chair Department of Pharmacology; Associate Director of Basic Science UCSD Moores Cancer Center; University of California, San Diego
Multinodal GNAQ Signaling-targeted Precision Therapy Approach for Metastatic Uveal Melanoma
- 4:05-4:25pm **TBD**
- 4:25-5:10pm Scientific Session 4: Rising Stars- Highlighting MRA Young Investigator Awardees**
Chair: Rachel Fischer, PhD; MRA Senior Scientific Program and Registry Manager
- 4:25-4:35pm **Zachary Buchwald, MD, PhD**; Assistant Professor in the Department of Radiation Oncology; Emory University School of Medicine
Enhancing an Abscopal Response by Elucidating the Role of Stem-Like T Cells
- 4:35-4:45pm **Tobias Bald, PhD**; Assistant Professor, Laboratory of Tumor-Immunobiology, University Hospital Bonn
Loss of Cd226 in T Cells Drives Melanoma Immunotherapy
- 4:45-4:55pm **Jeremy Logue, PhD**; Associate Professor, Regenerative and Cancer Cell Biology; Albany Medical College
Examining the Role of Blebs in Melanoma Metastasis
- 4:55-5:05pm **Haizhen (Jen) Wang, PhD**; Assistant Professor, Cell and Molecular Pharmacology, Medical University of South Carolina
Targeting PTPs for CDK6 Induced Immunotherapy Resistance in Melanoma

- 5:05-5:10pm **Closing Remarks Day 1: Stephanie Kauffman**, MRA President and COO
- 5:15-6:15pm MRA Board Meeting
- 5:15-6:45pm Poster Session I: Dermatology Fellows, Young Investigators, Pilot Awardees, and Sponsors
Light refreshments, all retreat attendees encouraged to attend
- 7:00-9:30pm Reception and Dinner
Reception: 7:00-7:30 pm; Dinner 7:30-9:30pm

Friday, March 10

- 6:30-10:00am Registration open
- 7:00-8:50am Breakfast and Poster Session II: Features Young Investigator Awardees
- 7:30-9:00am Industry Roundtable Breakfast (by invitation only)
- 9:00-9:05am **Opening Remarks Day 2: Joan Levy, PhD**; MRA Senior Director, Special Scientific Projects
- 9:05-9:35am **Keynote Lecture 2: Sohail Tavazoie, MD, PhD**; Hess Professor, Senior Attending Physician, The Rockefeller University
Development of New Therapeutics to Prevent Metastasis Through the Use of Systems Biology
- 9:35-11:30am **Scientific Session 5: Translation of new therapeutics from the lab to the clinic**
Chair: Genevieve Boland, MD, PhD; Director, Therapeutic Intralesional Program, Surgical Director, Termeer Center for Targeted Therapies, Massachusetts General Hospital
- 9:35-9:55am **Neta Erez, PhD**; Professor & Chair, Department of Pathology, Tel Aviv University
Targeting Neuroinflammation for Inhibition of Melanoma Brain Metastasis
- 9:55-10:15am **Alfonso Bellacosa, MD, PhD**; Professor Department of Cancer Epigenetics, The Research Institute of Fox Chase Cancer Center
Sensitizing Melanoma to Immunotherapy with Novel DNA Hypermethylating Drug
- 10:15-10:40am Break
- 10:40-11:05am **Jamie Spangler, PhD**; Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Johns Hopkins University School of Medicine
Immunotherapeutic Cytokine/Antibody Fusion Proteins to Treat Melanoma

11:05-11:30am **TBD**

11:30am-12:30pm **Panel Discussion: TBD**
Moderator:
Panelists:

12:30-12:45pm **Closing Remarks: Tanisha Jackson and Stephanie Kauffman**

12:45-1:45 pm Lunch and Departures

12:45-6:30pm Lunch and MRA & Seerave Foundation Melanoma & Microbiome Workshop (by invitation only)

6:30-9:30pm MRA & Seerave Foundation Melanoma & Microbiome Workshop - Dinner

Saturday, March 11

8:30am-1:30pm MRA & Seerave Foundation Melanoma & Microbiome Workshop (by invitation only)